BIOTECanada in collaboration with Innovative Medicines Canada responded to the Canadian Drug Agency’s consultation on its proposed Guidance for Incorporating Impacts on Informal Caregivers and Productivity Outcomes in Economic Evaluations. This reflects a positive step towards evolving HTA to better capture the full value of innovation by incorporating informal caregiver health-related quality of life, and patient and informal caregiver productivity outcomes. We recommend that the CDA-AMC expand its incorporation of the societal perspective for all submission types. The Guidance outlines what evidence sponsors must produce, and we recommend the CDA-AMC further elucidates how the data will be used in reimbursement decisions. The submission asks for flexibility in requirements vs. rigidity of data sources and provides a list of methodological considerations in the Appendix.
For more information, please contact Pascale Lajoie: pascale.lajoie@biotech.ca